DR. PAUL LEO FRANCIS GIANGRANDE

Dr. Paul Leo Francis GIANGRANDE
Nationality: England

Consultant Haematologist and Director, Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital , Oxford OX3 7LJ , UK

Current appointments:

1	Consultant Haematologist, Oxford Radcliffe Hospitals (since April 1991), Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford
2	Honorary Senior Lecturer in Haematology, University of Oxford (Member of Green College and Wolfson College).
3	Vice President (Medical) of the World Federation of Haemophilia and Chairman of the WFH Medical Advisory Board since 200: re-elected in October 2004 for further four-year term.

Academic qualifications :

1	BSc (Bachelor of Science, First Class) in Pharmacology, 1976
2	Graduated in Medicine (MB,ChB, awarded with Honours): Univ. Manchester, 1979
3	Doctor of Medicine (MD): 1991. Thesis entitled: "Lymphocyte activation in multitransfused haemophilic patients."
4	Fellow of the Royal Colleges of Physicians of London, Edinburgh and Ireland (FRCP, FRCP Ed, FRCPI)
5	Fellow of the Royal College of Pathologists (FRCPath)
6	Fellow of the Royal College of Paediatrics and Child Health (FRCPCH)

Professional activities:

1	I work exclusively in the field of haemostasis and thrombosis at the Oxford Haemophilia Centre and Thrombosis Unit. The Centre is located within the Churchill Hospital, an integral part of the Oxford Radcliffe Hospital NHS Trust. We provide a 24-hour clinical and laboratory service for both adults and children with a wide range of congenital and acquired disorder of coagulation, covering primarily the counties of Oxfordshire, Berkshire , Buckinghamshire and Northamptonshire. We also provide a diagnostic and treatment service for patients with deep venous thrombosis.
2	International role within WFH includes chairmanship of centre twinning programme, and Membership of TSE Task Force and Blood Safety Committees. Am also Member of steering committee of WFH/WHO/EQAS laboratory quality assurance scheme. I have travelled extensively on behalf of WFH in the last four years to 35 countries around the world for various activities including lecturing, workshops and meeting patient/doctor groups.
3	I am an Examiner in Haematology for the Royal College of Pathologists.
4	I am a member of the editorial boards of Haemophilia, Haematologica, Oral Disease and the International Journal of Clinical Practice
5	I have an interest in aviation medicine and serve as Honorary Consultant in Haematology to UK Civil Aviation Authority.

Previous appointments :

1	Research Fellow, Haemophilia and Thrombosis Centre, Milan, Italy, 1990-1991.
2	Research Fellow, Haemophilia Centre, Royal Free Hosp., London, 1987-1989.
3	Lecturer in Haematology at Westminster Medical School, 1984-1987.
4	Assistentarzt in the Kantonsspital, Basel, Switzerland, 1982-1983.

Selected recent publications :

1	Darby SC, Ewart DW, Giangrande PLF , Spooner RJD, Rizza CR et al: Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet 350: 1425-1431 (1997)
2	Management of haemophilia and von Willebrand's disease" and "Other disorders of coagulation": Giangrande PLF . In: Management of Haemophilia & other bleeding disorders: eds. Rizza CR and Lowe G (WB Saunders 1997)
3	Giangrande PLF : Management of pregnancy in carriers of haemophilia. Haemophilia 4: 779-784 (1998)
4	Martin PG, Sukhu K, Chambers E, Giangrande PLF : Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clinical and Laboratory Haematology 21: 125-128 (1999)
5	Giangrande PLF : The history of blood transfusion. Brit. J. Haematology. 110: 758-767 (2000)
6	Sukhu K, Keeling DM, Giangrande PLF : Variation in inhibitor reactivity in acquired haemophilia A with different concentrates. Clinical and Laboratory Haematology 22: 287-290 (2000)
7	Rizza CR, Spooner RJD, Giangrande PLF : Treatment of haemophilia in the UK 1981-1996. Haemophilia 7: 349-359 (2001)
8	"Molecular basis of haemophilia": Giangrande PLF . In: Molecular haematology (Blackwells, 1999 and new edition, 2005)
9	"Haematological problems in the surgical patient" Giangrande PLF , Littlewood TJ. In: Oxford Textboook of Surgery: eds. Morris PJ & Malt RA (OUP: 2000).
10	"Side-effects of hemostatic drugs" Giangrande PLF . In: Meyler's Side-Effects of Drugs, 14th ed. (2000)
11	Giangrande PLF for the Bayer Study Group. Safety and efficacy of Kogenate Bayer in previously untreated patients (PUP's) and minimally treated patients (MTPs). Haemophilia 8 Suppl 2: 19-22 (2002)
12	Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P , Ludlam C, Gringeri A, Berger K, Szucs T for the European Hemophilia Economic Study Group: Clinical outcomes and resource utilization associated with haemophilia care in Europe . Haemophilia 8: 33-43 (2002)
13	Ragni MV, Pasi KJ, White GC, Giangrande PL , Courter SG, Tubridy KL for the recombinant FIX surgical study group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 8: 91-97 (2002)
14	Giangrande PLF : Air travel and thrombosis. British Journal of Haematology 117: 509-512 (2002)
15	Battle J, Nova MS, Giangrande P , Lopez-Fernandez MF: Advances in the therapy of von Willebrand disease. Haemophilia 8: 301-307 (2002)
16	Giangrande PLF : Fondaparinux (Arixtra): a new anticoagulant. Journal of International Clinical Practice 56: 615-617 (2002).
17	Giangrande PLF , Kessler CM, Jenkins CE, Weatherill PJ, Webb PD: Viral pharmacovigilance study of porcine factor VIII. Haemophilia 8: 798-801 (2002).
18	Wilde JT, Lee CA, Darby SC, Kan SW, Giangrande P , Phillips AN, Winter M, Spooner R, Ludlam CA on behalf of the UK Haemophilia Centre Doctors' Organisation. The incidence of lymphoma in the UK haemophilia population. AIDS 16: 1803-1807 (2002)
19	"Air travel and thrombosis" and "Haematological disorders and blood transfusion" Giangrande PLF . In: Aviation and the airline passenger. Eds. Cummin ARC & Nicholson AN (Arnold: 2002)
20	Pregnancy in women with congenital bleeding disorders: Giangrande PLF In: Women's Issues in Thrombosis and Haemostasis. Eds. S. Brenner, V. Marder (Martin Dunitz: 2002)
21	Managing anticoagulation and fibrinolytic agents: Giangrande PLF . In: Textbook of Interventional Radiology:. Ed. J. Byrne (OUP, 2002)
22	Giangrande PLF : Air travel and thrombosis. British Journal of Haematology 117: 509-512 (2002)
23	Giangrande PLF : Treatment of hemophilia: recombinant factors only? Journal of Thrombosis and Haemostasis 1: 214-215 (2003)
24	Scully C, Watt-Smith P, Dios PD, Giangrande PLF : Complications in HIV-infected and non-HIV infected haemophiliacs and other patients after oral surgery. International Journal of Oral & Maxillofacial Surgery 31: 634-640 (2002)
25	Giangrande PLF , Mariani G, Black C: The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993-2003. Haemophilia 9: 240-4 (2003)
26	Giangrande PLF : Six characters in search of an author: the history of the nomenclature of coagulation factors. British Journal of Haematology 121: 703-712 (2003)
27	Giangrande PLF : von Willebrand disease. The Hematology Journal 4 (Suppl. 3):168-174 (2003)
28	Sukhu K, Poovalingam V, Mahomed R, Giangrande PLF : Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clinical and Laboratory Haematology 25: 247-249 (2003)
29	Chapman-Sheath PJ, Giangrande PLF , Carr AJ: Arthroplasty of the elbow in haemophilia. (British) Journal of Bone and Joint Surgery 85: 1138-1140 (2003).
30	Villar A, Aronis S, Morfini M, Santagostino E, Aurswald G, Thomsen HF, Erhardtsen, Giangrande PLF . Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 10: 1-8 (2004).
31	Darby SC, Keeling DM, Spooner RJD, Giangrande PLF, Collins PW, Hill FG. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. Journal of Thrombosis and Haemostasis 2:1047-54 (2004)
32	Giangrande PLF : Blood products for hemophilia-past, present and future. BioDrugs 18: 225-234 (2004).
33	Giangrande PLF. Haemophilia B : Christmas disease. Expert Opinion in Pharmacotherapy 6:1517-24 (2005)
34	Smith MP, Giangrande P, Pollamn H, Littlewood R, Kollmer C, Feingold J, and the Refacto St. Louis Study Group. A postmarketing surveillance study of the safety and efficacy of Refacto in patients with haemophilia A. Haemophilia 11: 444-451 (2005)